- Andrew Grigg1,*,
- Martin J.S. Dyer2,
- Marcos González Díaz3,
- Martin Dreyling4,
- Simon Rule5,
- Guiyuan Lei6,
- Andrea Knapp7,
- Elisabeth Wassner-Fritsch7 and
- Paula Marlton8
- 1 Department of Clinical Haematology, Austin Hospital, Heidelberg, Australia;
- 2 Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK;
- 3 Department of Hematology, University Hospital of Salamanca, Salamanca, Spain;
- 4 Department of Medicine III, LMU, Munich, Germany;
- 5 Department of Haematology, Derriford Hospital, Plymouth, UK;
- 6 Roche Products Ltd, Welwyn Garden City, United Kingdom;
- 7 F. Hoffmann-La Roche Ltd, Basel, Switzerland;
- 8 Princess Alexandra Hospital and University of Queensland School of Medicine, Brisbane, Australia
- ↵* Corresponding author; email:
The GAUDI study assessed safety and preliminary efficacy of induction therapy with obinutuzumab plus chemotherapy, followed by maintenance with obinutuzumab alone, in previously untreated patients with follicular lymphoma. Assignment to chemotherapy was decided on a per center basis before patient enrollment. Patients (n=81) received 4-6 cycles of obinutuzumab plus bendamustine every 4 weeks or 6-8 cycles of obinutuzumab plus CHOP every 3 weeks. Patients with an end-of-treatment response were eligible for obinutuzumab maintenance therapy every 3 months for 2 years or until disease progression. Induction treatment was completed by 90% of patients in the obinutuzumab plus bendamustine group and 95% in the obinutuzumab plus CHOP group, while maintenance was completed by 81% and 72% of patients, respectively. All patients experienced at least one adverse event during induction, most commonly infusion-related reactions (58%), the majority of which were grade 1/2. The most common hematologic adverse event was grade 3/4 neutropenia (36% during induction and 7% during maintenance). One treatment-related death occurred during the maintenance phase. At the end of induction, 94% of patients had achieved an overall response, with complete response based on CT in 36%. The progression-free survival rate at 36 months was 90% in the obinutuzumab plus bendamustine group and 84% in the obinutuzumab plus CHOP group. These results demonstrate that induction therapy with obinutuzumab plus bendamustine or obinutuzumab plus CHOP, followed by obinutuzumab maintenance, is associated with tolerable safety and promising efficacy. This study is registered at ClinicalTrials.gov as NCT00825149.
- Received July 11, 2016.
- Accepted December 22, 2016.
- Copyright © 2016, Ferrata Storti Foundation